Compare Cytokinetics Inc (CYTK) vs Liberty Global Ltd Class C (LBTYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Liberty Global Ltd Class C — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.63B), while Liberty Global Ltd Class C trades at $10.14 (market cap $3.48B). The key difference: Cytokinetics Inc is far larger — about 3.1× Liberty Global Ltd Class C's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Liberty Global Ltd Class C nearer its low. Which is the better fit depends on your goals.
| CYTK | LBTYK | |
|---|---|---|
Market Cap | $10.63B | $3.48B |
Sector | Technology | Technology |
52-Week High | $87.26 | $12.67 |
52-Week Low | $34.31 | $9.59 |
Enterprise Value | $10.74B | $10.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $75.64, down 2.39% on the day, amid a bearish technical signal despite a Q2 2026 earnings beat. The stock shows negative profitability with a net income margin of -1,321.12% and a high P/S ratio of 140.65, reflecting significant losses and premium valuation relative to sales. Recent news highlights strong uptake of MYQORZO and UK regulatory approval, supporting commercial momentum.
The outlook is polarized: analyst consensus is strongly bullish with a $111.14 price target, but high cash burn and competitive pressures pose risks. Investment opportunity hinges on MYQORZO's market expansion, while execution and funding needs remain key challenges for shareholders.
LBTYK trades at $10.13, up 1.4% on the day, amid a bearish technical signal from moving averages but neutral oscillators. The company reported mixed quarterly earnings, with a Q1 2026 beat but Q4 2025 and Q2 2026 misses, while full-year 2025 showed a net loss of $7.14B despite $4.88B revenue. Positive cash flow trends and the upcoming Ziggo Group spin-off in 2027 are key developments, with analyst sentiment leaning bullish with 69% buy ratings.
The outlook hinges on execution of asset monetizations and the Ziggo listing, offering upside from a discounted valuation, but high losses and competitive pressures pose significant risks. Investors should weigh the sum-of-parts opportunity against persistent profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Liberty Global Ltd Class C
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →
